NYSEAMERICAN:NAVB Navidea Biopharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.67 -0.01 (-1.33%) (As of 07/5/2022 12:02 PM ET) Add Compare Share Today's Range$0.66▼$0.6750-Day Range N/A52-Week Range$0.56▼$1.96Volume1,350 shsAverage Volume218,610 shsMarket Capitalization$20.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Navidea Biopharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.72 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Navidea Biopharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.23% of the outstanding shares of Navidea Biopharmaceuticals have been sold short.Short Interest Ratio / Days to CoverNavidea Biopharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Navidea Biopharmaceuticals has recently decreased by 16.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNavidea Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNavidea Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAVB. Previous Next 2.8 News and Social Media Coverage News SentimentNavidea Biopharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Navidea Biopharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Navidea Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders32.40% of the stock of Navidea Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.22% of the stock of Navidea Biopharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Navidea Biopharmaceuticals is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Navidea Biopharmaceuticals is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNavidea Biopharmaceuticals has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) StockNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Read More NAVB Stock News HeadlinesJuly 5, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Additional Bridge Loan FundingMay 24, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual MeetingMay 12, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Reports First Quarter 2022 Financial ResultsApril 20, 2022 | seekingalpha.comNavidea reports initial data from phase 2b study of imaging agent in rheumatoid arthritis patientsApril 20, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU MarketsApril 20, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid ArthritisApril 19, 2022 | seekingalpha.comNavidea stock soars ~20%, to get patents in US, JapanApril 18, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in IndiaApril 13, 2022 | marketwatch.comNavidea Biopharma Shares Rise 10% After Loan Agreement ClosesApril 12, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Receives Acceptance Letter from NYSE AmericanApril 12, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A SeriesApril 7, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory AffairsMarch 23, 2022 | apnews.comCORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial ResultsMarch 22, 2022 | markets.businessinsider.comHere's what to expect from Navidea Biopharmaceuticals's earningsMarch 16, 2022 | finance.yahoo.comNavidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business UpdateFebruary 7, 2022 | seekingalpha.comNavidea in research pact to evaluate Tc99m tilmanocept as a prognostic markerFebruary 7, 2022 | benzinga.comNavidea Shares Jump On Research Pact For Tc99m Tilmanocept As Biomarker In Brain CancerFebruary 7, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for GlioblastomaFebruary 3, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE AmericanDecember 16, 2021 | finance.yahoo.comNavidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid ArthritisDecember 16, 2021 | finance.yahoo.comNavidea Shares Gain After Terminating Stock Purchase AgreementDecember 15, 2021 | finance.yahoo.comNavidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis ProgramDecember 15, 2021 | finance.yahoo.comNavidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis ProgramDecember 15, 2021 | finance.yahoo.comNavidea Biopharmaceuticals Terminates Stock Purchase AgreementDecember 13, 2021 | finance.yahoo.comNavidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid ArthritisSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSEAMERICAN:NAVB Previous SymbolNYSEMKT:NAVB CUSIP63937X10 CIK810509 Webwww.navidea.com Phone(614) 793-7500Fax614-793-7522Employees11Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,720,000.00 Net Margins-1,557.43% Pretax Margin-1,555.14% Return on Equity-116.36% Return on Assets-114.53% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.83 Sales & Book Value Annual Sales$920,000.00 Price / Sales22.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book1.46Miscellaneous Outstanding Shares30,360,000Free Float20,407,000Market Cap$20.34 million OptionableOptionable Beta1.73 Navidea Biopharmaceuticals Frequently Asked Questions Are investors shorting Navidea Biopharmaceuticals? Navidea Biopharmaceuticals saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 69,500 shares, a decrease of 16.3% from the May 31st total of 83,000 shares. Based on an average trading volume of 355,500 shares, the short-interest ratio is presently 0.2 days. View Navidea Biopharmaceuticals' Short Interest. When is Navidea Biopharmaceuticals' next earnings date? Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Navidea Biopharmaceuticals. How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter. Navidea Biopharmaceuticals had a negative net margin of 1,557.43% and a negative trailing twelve-month return on equity of 116.36%. View Navidea Biopharmaceuticals' earnings history. Who are Navidea Biopharmaceuticals' key executives? Navidea Biopharmaceuticals' management team includes the following people: Ms. Erika L. Eves, VP of Fin. & Admin. (Age 52, Pay $213.25k)Dr. Michael Stanley Rosol Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $336.31k)Mr. Jeffrey G. Smith, VP of Operations Who are some of Navidea Biopharmaceuticals' key competitors? Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX). View all of NAVB's competitors. What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA). What is Navidea Biopharmaceuticals' stock symbol? Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB." How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Navidea Biopharmaceuticals' stock price today? One share of NAVB stock can currently be purchased for approximately $0.67. How much money does Navidea Biopharmaceuticals make? Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $20.34 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. How many employees does Navidea Biopharmaceuticals have? Navidea Biopharmaceuticals employs 11 workers across the globe. How can I contact Navidea Biopharmaceuticals? Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for Navidea Biopharmaceuticals is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522. This page (NYSEAMERICAN:NAVB) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
